tiprankstipranks
Trending News
More News >

Forte Biosciences Announces Positive Phase 1b Trial Results

Story Highlights
Forte Biosciences Announces Positive Phase 1b Trial Results

Don’t Miss TipRanks’ Half-Year Sale

Forte Biosciences ( (FBRX) ) just unveiled an announcement.

On June 23, 2025, Forte Biosciences announced positive results from its Phase 1b trial for FB102 in celiac disease, demonstrating significant benefits in histological and symptomatic endpoints. The company plans to initiate a Phase 2 trial with a topline readout expected in 2026, marking a significant step toward addressing unmet needs in celiac disease and potentially benefiting other indications like vitiligo, alopecia areata, and type 1 diabetes.

The most recent analyst rating on (FBRX) stock is a Buy with a $68.75 price target. To see the full list of analyst forecasts on Forte Biosciences stock, see the FBRX Stock Forecast page.

Spark’s Take on FBRX Stock

According to Spark, TipRanks’ AI Analyst, FBRX is a Underperform.

Forte Biosciences faces significant challenges with no revenue and increasing operational losses, leading to a weak financial performance. Technical analysis indicates a mixed outlook with bearish long-term trends. The negative P/E ratio and lack of dividend yield highlight valuation concerns. Without positive developments in these areas, the stock remains highly speculative and risky.

To see Spark’s full report on FBRX stock, click here.

More about Forte Biosciences

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate, for potentially broad autoimmune and autoimmune-related indications.

Average Trading Volume: 47,794

Technical Sentiment Signal: Hold

Current Market Cap: $96.51M

Find detailed analytics on FBRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1